Literature Citations
1. In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria. Brown-Elliott, B.A. and R.J. Wallace, Jr. Antimicrobial Agents and Chemotherapy, 2021. 65(3): e01947-01920. PMID[33288634].
[PubMed]. TB_02_2021.
2. Schiff-base Silver Nanocomplexes Formation on Natural Biopolymer Coated Mesoporous Silica Contributed to the Improved Curative Effect on Infectious Microbes. Cai, L., Y.Q. Huang, Y.Y. Duan, Q. Liu, Q.L. Xu, J. Jia, J.M. Wang, Q. Tong, P.P. Luo, Y.J. Wen, L.M. Peng, Q. Wu, X.D. Hang, H.J. Jiang, P. Zhu, Y.M. Yang, B.S. Zhou, L.P. Zeng, H.K. Bi, and J. Chen. Nano Research, 2021. 38(1).
ISI[000609378500001].
[WOS]. TB_02_2021.
3. Synthesis and Structure-activity Studies of Novel Anhydrohexitol-based Leucyl-tRNA Synthetase Inhibitors. De Ruysscher, D., L. Pang, S.M.G. Lenders, D. Cappoen, P. Cos, J. Rozenski, S.V. Strelkov, S.D. Weeks, and A. Van Aerschot. European Journal of Medicinal Chemistry, 2021. 211: 113021. PMID[33248851].
[PubMed]. TB_02_2021.
4. Design, Synthesis, and Biological Evaluation of Benzo[d]imidazole-2-carboxamides as New anti-TB Agents. Dhameliya, T.M., K.I. Patel, R. Tiwari, S.K. Vagolu, D. Panda, D. Sriram, and A.K. Chakraborti. Bioorganic Chemistry, 2021. 107: 104538. PMID[33349456].
[PubMed]. TB_02_2021.
5. Design, Synthesis, in Vitro and in Silico Evaluation of New 3-Phenyl-4,5-dihydroisoxazole-5-carboxamides Active against Drug-resistant Mycobacterium tuberculosis. Gaikwad, N.B., P. Afroz, M.N. Ahmad, G. Kaul, M. Shukla, S. Nanduri, A. Dasgupta, S. Chopra, and V.M. Yaddanapudi. Journal of Molecular Structure, 2021. 1227: 129545. ISI[000609153400016].
[WOS]. TB_02_2021.
6. Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions. Ginn, J., X. Jiang, S. Sun, M. Michino, D.J. Huggins, Z. Mbambo, R. Jansen, K.Y. Rhee, N. Arango, C.D. Lima, N. Liverton, T. Imaeda, R. Okamoto, T. Kuroita, K. Aso, A. Stamford, M. Foley, P.T. Meinke, C. Nathan, and R. Bryk. ACS Infectious Diseases, 2021. 7(2): p. 435-444. PMID[33527832]. PMCID[PMC7888283].
[PubMed]. TB_02_2021.
7. Analogues of the Herbicide, N-Hydroxy-N-isopropyloxamate, Inhibit Mycobacterium tuberculosis Ketol-acid Reductoisomerase and Their Prodrugs are Promising anti-TB Drug Leads. Kandale, A., K. Patel, W.M. Hussein, S.J. Wun, S. Zheng, L. Tan, N.P. West, G. Schenk, L.W. Guddat, and R.P. McGeary. Journal of Medicinal Chemistry, 2021. 64(3): p. 1670-1684. PMID[33512163].
[PubMed]. TB_02_2021.
8. Identification of a Mycobacterium tuberculosis Cyclic Dinucleotide Phosphodiesterase Inhibitor. Karanja, C.W., K.S. Yeboah, and H.O. Sintim. ACS Infectious Diseases, 2021. 7(2): p. 309-317. PMID[33492938].
[PubMed]. TB_02_2021.
9. Isolation and Identification of Streptomyces sp. Act4Zk, a Good Producer of Staurosporine and Some Derivatives. Khosravi Babadi, Z., G. Ebrahimipour, J. Wink, A. Narmani, and C. Risdian. Letters in Applied Microbiology, 2021. 72(2): p. 206-218. PMID[33058293].
[PubMed]. TB_02_2021.
10. Minimal Inhibitory Concentration of Clofazimine among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. Kwak, N., J. Whang, J.S. Yang, T.S. Kim, S.A. Kim, and J.J. Yim. Chest, 2021. 159(2): p. 517-523. PMID[32712225].
[PubMed]. TB_02_2021.
11. Discovery of a Pyrimidinedione Derivative with Potent Inhibitory Activity against Mycobacterium tuberculosis Ketol-acid Reductoisomerase. Lin, X., J.L. Kurz, K.M. Patel, S.J. Wun, W.M. Hussein, T. Lonhienne, N.P. West, R.P. McGeary, G. Schenk, and L.W. Guddat. Chemistry, 2021. 27(9): p. 3130-3141. PMID[33215746].
[PubMed]. TB_02_2021.
12. Synthesis and Activity of BNF15 against Drug-resistant Mycobacterium tuberculosis. Mahmud, H.A., H. Seo, S. Kim, M.I. Islam, O.F. Sultana, K.W. Nam, B.E. Lee, V.S. Sadu, K.I. Lee, and H.Y. Song. Future Medicinal Chemistry, 2021. 13(3): p. 251-267. PMID[33295787].
[PubMed]. TB_02_2021.
13. Evaluation of the Antimicrobial Effect of the Extracts of the Pods of Piliostigma thonningii (Schumach.) Milne-Redh. (Fabaceae). Makosa, M., S. Sithole, and S. Mukanganyama. Advances in Pharmacological and Pharmaceutical Sciences, 2021. 2021: 6616133. PMID[33629066]. PMCID[PMC7896843].
[PubMed]. TB_02_2021.
14. Synthesis and Evaluation of New Quinazoline-benzimidazole Hybrids as Potent Anti-microbial Agents against Multidrug Resistant Staphylococcus aureus and Mycobacterium tuberculosis. Malasala, S., M.N. Ahmad, R. Akunuri, M. Shukla, G. Kaul, A. Dasgupta, Y.V. Madhavi, S. Chopra, and S. Nanduri. European Journal of Medicinal Chemistry, 2021. 212: 112996. PMID[33190958].
[PubMed]. TB_02_2021.
15. Soybean Lectin Induces Autophagy through P2RX7 Dependent Activation of NF- κB-ROS Pathway to Kill Intracellular Mycobacteria. Mishra, A., A. Behura, A. Kumar, A. Ghosh, L. Naik, S. Mawatwal, S.S. Mohanty, A. Mishra, S. Saha, S.K. Bhutia, R. Singh, and R. Dhiman. Biochimica et Biophysica Acta General Subjects, 2021. 1865(2): p. 129806. PMID[33253803].
[PubMed]. TB_02_2021.
16. Edible Marine Algae: A New Source for Anti-mycobacterial Agents. Mukherjee, G., B. Mukhopadhyay, and A.K. Sil. Folia Microbiologica, 2021. 66(1): p. 99-105. PMID[32975727].
[PubMed]. TB_02_2021.
17. Anti-TB Efficacy of PBTZ169 in Mice with Different Genetic Susceptibility to Infection. Nikonenko, B., V. Makarov, I. Bocharova, M. Korotetskaya, E. Kondratieva, N. Sterzhanova, and A. Apt. European Respiratory Journal, 2020. 56: 2805. ISI[000606501405311].
[WOS]. TB_02_2021.
18. Unbiased Identification of Angiogenin as an Endogenous Antimicrobial Protein with Activity against Virulent Mycobacterium tuberculosis. Noschka, R., F. Gerbl, F. Loffler, J. Kubis, A.A. Rodriguez, D. Mayer, M. Grieshober, A. Holch, M. Raasholm, W.G. Forssmann, B. Spellerberg, S. Wiese, G. Weidinger, L. Standker, and S. Stenger. Frontiers in Microbiology, 2021. 11: 618278. PMID[33537017]. PMCID[PMC7848861].
[PubMed]. TB_02_2021.
19. Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. Oh, S., M.D.J. Libardo, S. Azeeza, G.T. Pauly, J.S.O. Roma, A. Sajid, Y. Tateishi, C. Duncombe, M. Goodwin, T.R. Ioerger, P.G. Wyatt, P.C. Ray, D.W. Gray, H.I.M. Boshoff, and C.E. Barry, 3rd. ACS Infectious Diseases, 2021. 7(2): p. 479-492. PMID[33405882]. PMCID[PMC7887755].
[PubMed]. TB_02_2021.
20. Synthesis of Carbapenems Containing Peptidoglycan Mimetics and Inhibition of the Cross-linking Activity of a Transpeptidase of l,d Specificity. Saidjalolov, S., Z. Edoo, M. Fonvielle, L. Mayer, L. Iannazzo, M. Arthur, M. Etheve-Quelquejeu, and E. Braud. Chemistry, 2021. 27(10): p. 3542-3551. PMID[33336443].
[PubMed]. TB_02_2021.
21. Synthesis, in Vitro Antibacterial Activity against Mycobacterium tuberculosis, and Reverse Docking-based Target Fishing of 1,4-Benzoxazin-2-one Derivatives. Stepanova, E.E., S.Y. Balandina, V.A. Drobkova, M.V. Dmitriev, I.V. Mashevskaya, and A.N. Maslivets. Archiv der Pharmazie, 2021. 354(2): e2000199. PMID[33617016].
[PubMed]. TB_02_2021.
22. In-Vitro Effect of Bioactive Fractions of Cinnamomum verum(CV) on Cytokine Levels in Mycobacterium tuberculosis (MTB) Infected Macrophages. Vaidya, S., J. Maniar, and J. Sharma. European Respiratory Journal, 2020. 56: 2803. ISI[000606501405309].
[WOS]. TB_02_2021.
23. Structure-based Drug Design, Synthesis and Screening of MmaA1 Inhibitors as Novel anti-TB Agents. Veeravarapu, H., V. Malkhed, K.K. Mustyala, R. Vadija, R. Malikanti, U. Vuruputuri, and M.K.K. Muthyala. Molecular Diversity, 2021. 25(1): p. 351-366. PMID[32533514].
[PubMed]. TB_02_2021.
24. A Sensitive EZMTT Method Provides Microscale, Quantitative and High-throughput Evaluation of Drug Efficacy in the Treatment of Mycobacterium tuberculosis Infectious Diseases. Xie, L., Z. Chen, W. Liu, D. Gu, Y. Yu, X. Chen, Y. Wu, N. Xu, J. Xie, G. Zhao, and B.H. Ruan. Journal of Microbiological Methods, 2021. 181: 106136. PMID[33422524].
[PubMed]. TB_02_2021.
Patent Citations
25. Compounds Exhibiting Anti-tuberculosis Activity. Turan, G., M. Demirel, and I. Namli. Patent. 2021. 2020-TR50232 2021025644: 22pp.
[Patent]. TB_02_2021.